Browsing Tag
SRX-25
1 post
InhaleRx (ASX: IRX) unveils oral esketamine therapy for depression but stock sinks 22% amid investor caution
InhaleRx launches SRX-25 oral esketamine therapy for depression, plans rebrand and raises capital despite 22% stock plunge. Learn what this could mean for investors.
November 26, 2025